Abstract
Objective: Rearranged during transfection (RET) mutations are well-known genetic events in sporadic and familial medullary thyroid carcinoma (FMTC). The presence ofRASmutations in sporadic cases, challenging theRETparadigm in these tumors, has been recently reported. We intend to evaluate mTOR pathway activation inRET- andRAS-mutated MTC.Materials and methods: In this study, we analysed the presence ofRET, H-RAS, andK-RASmutations in a series of 87 MTCs (82 apparently sporadic and five FMTCs; five apparently sporadic MTCs were eventually found to be familial). We also evaluated mTOR activation – using the expression of its downstream effector phospho-S6 ribosomal protein (p-S6) and the expression of the mTOR inhibitor, phosphatase and tensin homologue deleted on chromosome 10 (PTEN) – by immunohistochemistry.Results: Our results revealed thatRETmutations were present in 52.9% of the cases (46/87) andRASmutations in 12.6% (11/87) of the whole series of MTCs and 14.3% of the 77 sporadic MTCs. The presence ofRETandRASmutations was mutually exclusive.RASmutations were significantly associated with higher intensity of p-S6 expression (P=0.007), suggesting that the mTOR pathway is activated in such MTCs. We observed also an increased expression of p-S6 in invasive tumors (P=0.042) and in MTCs with lymph node metastases (P=0.046). CytoplasmicPTENexpression was detected in 58.8% of the cases; cases WT forRASshowed a significantly lower expression ofPTEN(P=0.045).Conclusions: We confirmed the presence ofRASmutation in 14.3% of sporadic MTCs and report, for the first time, an association between such mutations and the activation of the mTOR pathway. The evaluation of the mTOR activation by pS6 expression may serve as an indicator of invasive MTC.

This publication has 22 references indexed in Scilit: